387 related articles for article (PubMed ID: 31320597)
1. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
Wen PY; Reardon DA; Armstrong TS; Phuphanich S; Aiken RD; Landolfi JC; Curry WT; Zhu JJ; Glantz M; Peereboom DM; Markert JM; LaRocca R; O'Rourke DM; Fink K; Kim L; Gruber M; Lesser GJ; Pan E; Kesari S; Muzikansky A; Pinilla C; Santos RG; Yu JS
Clin Cancer Res; 2019 Oct; 25(19):5799-5807. PubMed ID: 31320597
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS
Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020
[TBL] [Abstract][Full Text] [Related]
3. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
5. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
7. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
[TBL] [Abstract][Full Text] [Related]
8. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Ardon H; Van Gool SW; Verschuere T; Maes W; Fieuws S; Sciot R; Wilms G; Demaerel P; Goffin J; Van Calenbergh F; Menten J; Clement P; Debiec-Rychter M; De Vleeschouwer S
Cancer Immunol Immunother; 2012 Nov; 61(11):2033-44. PubMed ID: 22527250
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
Bhaskaran D; Savage J; Patel A; Collinson F; Mant R; Boele F; Brazil L; Meade S; Buckle P; Lax S; Billingham L; Short SC
BMC Cancer; 2024 Jan; 24(1):83. PubMed ID: 38225549
[TBL] [Abstract][Full Text] [Related]
11. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Fadul CE; Fisher JL; Hampton TH; Lallana EC; Li Z; Gui J; Szczepiorkowski ZM; Tosteson TD; Rhodes CH; Wishart HA; Lewis LD; Ernstoff MS
J Immunother; 2011 May; 34(4):382-9. PubMed ID: 21499132
[TBL] [Abstract][Full Text] [Related]
12. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y;
BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
17. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
[TBL] [Abstract][Full Text] [Related]
18. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
19. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]